Current principles of diabetes management
|
|
- Bernard Golden
- 5 years ago
- Views:
Transcription
1 Current principles of diabetes management Prof. Martin Haluzík, MD, DSc. 3 Department of Medicine, General University Hospital and 1st Faculty of Medicine, Charles University in Prague, Czech Republic
2 Why do we need to treat DM? - To suppress the negative effects of excessive hyperglycemia (polydypsia, polyuria, weight loss) To prevent chronic microvascular (neuropathy, nephropathy, retinopathy) and macrovascular complications (MI, stroke, PVD) The ultimate goal is to prevent premature death and to enable the patient good quality of life (optimally without chronic complications)
3 Key challenges of type 2 diabetes 1. Diabetes is a progressive disease characterised by: Declining beta-cell function Deterioration of glycaemic control Increased risk of cardiovascular disease 2. As diabetes treatments are added to control glucose, physicians and patients face trade-offs such as: Hypoglycaemia Weight gain Complex treatment regimens (multiple daily dosing and need for self-monitoring of blood glucose)
4 T2DM is a complex disease associated with a high risk of CV complications 79 % of T2DM patients are overweight or obese 63 % of T2DM patients have arterial hypertension 70 % of T2DM patients have dyslipidemia Libby et al. Circulation 2002;106(22): Jacobs et al. Diabetes Res Clin Pract. 2005;70(3):
5 Hazard ratio Hazard ratio Higher HbA 1c predicts higher CV risk 10 Fatal and non-fatal MI 10 Fatal and non-fatal stroke p< p= % decrease per 1% reduction in HbA 1c 12% decrease per 1% reduction in HbA 1c Amputation/death from PVD 10 Heart failure p< p= % decrease per 1% reduction in HbA 1c 16% decrease per 1% reduction in HbA 1c HbA 1c (%) HbA 1c (%) Reference category (hazard ratio 1.0) is HbA 1c <6% with log linear scales CV, cardiovascular; HbA 1c, glycosylated haemoglobin; MI, myocardial infarction; PVD, peripheral vascular disease Stratton IM et al. BMJ 2000;321:
6 STENO-2: Treatment targets Conventional Therapy Intensive Therapy Systolic blood pressure (mmhg) < 160 < 135 < 140 < 130 Diastolic blood pressure (mmhg) < 95 < 85 < 85 < 80 HbA 1c (%) < 7.5 < 6.5 < 6.5 < 6.5 Fasting serum total cholesterol (mmol/l) < 6.5 < 4.9 < 4.9 < 4.5 Fasting serum triglycerides (mmol/l) < 2.2 < 2.0 < 1.7 < 1.7 Treatment with ACE-inhibitor irrespective of blood pressure No Yes Yes Yes Aspirin therapy: Known ischaemia Yes Yes Yes Yes Peripheral vascular disease No No Yes Yes No known CHD or peripheral vascular disease No No No Yes ACE, angiotensin-converting enzyme; CHD, coronary heart disease; HbA 1c, glycated haemoglobin Gæde P et al. Diabetologia 2016;59:
7 Proportion of patients that died (%) Cumulative mortality (%) STENO-2: Mortality at 21 years follow-up End of trial and start of intensification of conventional-therapy group patients treatment 80 HR: % CI: p= Conventional Intensive % years Median survival time % 25 Difference in median survival time of at least 7.9 years* Years since randomisation 0 Conventional therapy Intensive therapy *No formal calculation possible as <50% mortality in intensive therapy group. CI, confidence interval; HR, hazard ratio Gæde P et al. Diabetologia 2016;59: Number at risk Intensive Convention al
8 Cumulative incidence of death or CVD event (%) Median time to first CVD event or death (years) STENO-2: Time to first CVD event or death 100 End of trial and start of intensification of conventional-therapy group patients treatment 18 ETD: 8.1 years 95% CI: Median CVD-free survival time Years since randomisation 2 Number at risk Intensive Convention al CI, confidence interval; CVD, cardiovascular disease; ETD, estimated treatment difference Gæde P et al. Diabetologia 2016;59: Conventional therapy Intensive therapy
9 Lifestyle modifications in the treatment of T2DM - Stop smoking - Low calorie diet with restriction of simple carbohydrates (sweets, sugar drinks, sweet fruits), saturated fats, salt (patients with hypertension), no special diabetic foodstuffs! no food supplements! - Regular exercixe (optimally steps/day) Long term goal decrease or at least maintenance of the current body weight (decrease of body weight of 5-10 % significantly decreases CV risk - fit-fat vs. unfit-unfat Repeated patients education needed
10 An average day at the outpatient clinic 56 years male 12 yrs T2DM BMI 31.6 Smoking Laser for DRP AMI 2 yrs earlier PNP Overt proteinuria HbA1c 8.9% 56 years male 4 yrs T2DM BMI 31.6 Never smoked No DRP No microalbuminuria No PNP Cycles to work HbA1c 8.9% Similar glycaemic targets?????
11 11 Inzucchi S E et al. Diabetes Care 2012;35:
12 Why the goals should not be the same or should they? Optimally, we would like to achieve euglycemia in all patients regardless of diabetes duration and complications The problem is that we cannot do that without risk of hypoglycemia, weight gain and other side effects of some of the current therapies It may well be that all diabetics would benefit from tight control if this can be done without major side effects
13 Major principles: The overall goal is to prevent or delay the development of micro- and macrovascular complications Early diagnosis and intensive pharmacological treatment immediately after diagnosis (metformin) target Hb1Ac % In high-risk patients with long history of T2DM and unsatisfactory control the targets should be less ambitious (Hb1AC %) Avoid hypoglycemia, weight gain Intensive life-style measures and education of patients (diet, body weight, physical activity) Intensive intervention of CV risk factors (BP, lipids, smoking cessation
14 New vs.old drugs: are we getting there? Old drugs Metformin Pioglitazone Sulphonylureas Glinides -glucosidase inhibitors Human insulins older insulin analogues New drugs DPP-4 inhibitors (gliptins) GLP-1 receptor agonists SGLT-2 inhibitors New insulin analogues
15 Targeting the ominous octet: initial triple combination vs. stepwise tretament intensification Design: 147 newly diagnosed T2DM patients randomized to: - Initial combination of metformin 2000 mg pioglitazone 45 mg exenatide 2 x 10 ug vs. - Stepwise intensification: metformin 1000 mg 2000 mg glipizide basal NPH insulin After 24 months of treatment: HbA1c: from 8,6 % (DCCT) to 6,1 % in initial triple combination vs. 6,6 % in stepwise intensification Hypoglycemia: 13,6 lower rate in initial triple combination Body weight: by 1,2 kg in initial triple combination vs. 3,6 kg in stepwise intensification DeFronzo et al, Diabetes, 2013; Abdul-Ghani et al, ADA, 2013
16 Experience with rosiglitazone: are diabetes medications associated with increased CV risk? Rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance CV, cardiovascular Nissen SE et al. N Engl J Med 2007;156:
17 The change in the paradigm of antidiabetic treatment goals From glucocentricity to reduction of CV risk and mortality CV, cardiovascular; HbA 1c, glycosylated haemoglobin
18 DPP-4i DPP-4i Saxagliptin and cardiovascular outcomes in patients with T2DM Alogliptin after acute coronary syndrome in patients with T2DM DPP-4i GLP-1RA Effect of sitagliptin on cardiovascular outcomes in T2DM Lixisenatide in acute coronary syndrome, a longterm cardiovascular end point trial of lixisenatide vs placebo SGLT2i GLP-1RA Empagliflozin, cardiovascular outcomes and mortality in T2DM Liraglutide and cardiovascular outcomes in T2DM GLP-1RA GLP-1RA SUSTAIN 6: cardiovascular and other long-term outcomes with semaglutide in subjects with T2DM FREEDOM-CVO: placebo-controlled cardiovascular outcomes study examining the safety of ITCA 650 vs placebo DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonist; SGLT2i, sodium glucose co transporter 2 inhibitor; T2DM, type 2 diabetes mellitus
19 SAVOR-TIMI-53 1 EXAMINE 2 T2DM; HbA 1c %; 40 years + CVD; 55 (men) or 60 (women) years + CV risk factors (n=16,492) Saxagliptin (2.5 or 5 mg/day) + standard of care Placebo + standard of care T2DM; HbA 1c %; ACS within days (n=5,380) Alogliptin (6.25, 12.5 or 25 mg/day) + standard of care Placebo + standard of care TECOS 3 ELIXA 4 T2DM; HbA 1c %; 50 years; CVD history (n=14,671) Sitagliptin (100 or 50 mg/day) + standard of care Placebo + standard of care T2DM; HbA 1c %; ACS within 180 days (n=6,068) Lixisenatide (10 or 20 mg/day) + standard of care Placebo + standard of care ACS, acute coronary syndrome; CI, confidence interval; CV, cardiovascular; EXAMINE, Examination of Cardiovascular Outcomes: Alogliptin vs. Standard of Care in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome; HR, hazard ratio; MI, myocardial infarction; SAVOR TIMI-53, Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Thrombolysis in Myocardial Infarction 53; T2DM, type 2 diabetes; TECOS, Trial Evaluating Cardiovascular Outcomes with Sitagliptin; T2DM, type 2 diabetes; UA, unstable angina 1. Sciria et al. N Engl J Med 2013;369(14): ; 2. White et al. N Engl J Med 2013;369(14): ; 3. Green et al. N Engl J Med 2015;16;373(3): ; 4. Pfeffer MA et al. N Engl J Med 2015;373:
20 Patients with event (%) EMPA-REG OUTCOME Study design and inclusion criteria EMPAGLIFLOZIN 25 mg once daily Placebo EMPAGLIFLOZIN 10 mg once daily 20 Time to first occurrence of CV death, non-fatal MI, or non-fatal stroke Hazard ratio (95.02% CI): 0.86 ( ) p=0.04 for superiority Placebo once daily 15 Screening Placebo run-in Randomisation (1:1:1) Treatment period Median duration: 2.6 years Median observation time: 3.1 years End of treatment Followup +30 days 10 N=7028 T2DM with established CV disease Age: 18 years; 20 years in Japan; 65 years in India Drug-naive and HbA 1c 7.0 to 9.0% or stable background antidiabetes therapy* and HbA 1c 7.0 to 10.0% BMI 45.0 kg/m 2 and egfr 30 ml/min/1.73m Empagliflozin Placebo Primary endpoint Three-point MACE time to first occurrence of: CV death, non-fatal MI, or non-fatal stroke Month No. at risk Empaglifl ozin Placebo *Except pioglitazone in Japan; Excluding silent MI Background glucose-lowering therapy unchanged in first 12 weeks, then adjusted at the investigator s discretion to achieve desired glycaemic control BMI, body mass index; CI, confidence interval; CV, cardiovascular; egfr, estimated glomerular filtration rate; HbA 1c, glycosylated haemoglobin; MACE, major adverse cardiovascular event; MI, myocardial infarction; T2DM, type 2 diabetes mellitus Zinman B et al. Cardiovasc Diabetol 2014;13:102; Zinman B et al. N Engl J Med 2015;373:
21 Patients with event (%) EMPA-REG OUTCOME: CV death 9 Placebo Hazard ratio (95% CI): 0.62 ( ) p< Empagliflozin Month Number at risk Empagliflozi n Placebo CI, confidence interval; CV, cardiovascular Zinman B et al. N Engl J Med 2015;373:
22 Patients with event (%) EMPA-REG OUTCOME: Hospitalisation for heart failure Hazard ratio (95% CI): 0.65 ( ) p=0.002 Placebo 4 3 Empagliflozin Month Number at risk Empagliflozi n Placebo CI, confidence interval; CV, cardiovascular Zinman B et al. N Engl J Med 2015;373:
23 Patients with an event (%) LEADER Study design and inclusion criteria Time to CV death, non-fatal MI, or non-fatal stroke Placebo Liraglutide mg OD + standard of care Placebo + standard of care Safety follow up Safety follow up Hazard ratio (95% CI) 0.87 (0.78 ; 0.97) p<0.001 for non-inferiority p=0.01 for superiority P la c e b o Placebo 2 weeks Duration years 30 days N=9340 T2DM, HbA 1c 7.0% Antidiabetic drug naïve; OADs and/or basal/premix insulin Age 50 years; established CV disease or chronic renal failure or age 60 years and risk factors for CV disease Primary endpoint Time from randomisation to first occurrence of a composite CV outcome (CV death, non-fatal MI, or non-fatal stroke) Patients at risk Liraglutide 4668 Placebo L ir a g lu t id e Time from randomisation (months) Liraglutide The primary composite outcome in the time-to-event analysis was the first occurrence of death from cardiovascular causes, non-fatal myocardial infarction, or nonfatal stroke. The cumulative incidences were estimated with the use of the Kaplan Meier method, and the hazard ratios with the use of the Cox proportional-hazard regression model. The data analyses are truncated at 54 months, because less than 10% of the patients had an observation time beyond 54 months CV, cardiovascular; HbA 1c, glycosylated haemoglobin; MI, myocardial infarction; OAD, oral antidiabetic drug; OD, once daily; T2DM, type 2 diabetes mellitus Marso SP et al. N Engl J Med 2016;375:
24 Subjects with an event (%) Semaglutide is an investigational product and not currently approved SUSTAIN 6 Study design and inclusion criteria Semaglutide 1.0 mg Semaglutide 0.5 mg Placebo 1.0 mg Time to first occurrence of CV death, non-fatal MI or non-fatal stroke Hazard ratio (95% CI) 0.74 ( ) Events: 108 semaglutide; 146 placebo p<0.001 for non-inferiority p=0.02 for superiority Placebo, 8.9% Placebo 0.5 mg Dose escalation * 4 8 weeks Maximum trial duration 104 weeks Follow-up 5 weeks 5 Semaglutide, 6.6% 3297 patients T2DM with HbA 1c 7.0% 0 2 OADs ± basal or pre-mix insulin Time since randomisation (weeks) Primary endpoint Time from randomisation to first occurrence of a MACE, defined as CV death, non-fatal MI, or non-fatal stroke Semaglutid e Number of patients at risk Placebo *Fixed dose-escalation: starting dose 0.25 mg for 4 weeks, escalated to 0.5 mg for 4 weeks until maintenance dose (0.5 mg or 1.0 mg); CV, cardiovascular; HbA 1c, glycosylated haemoglobin; MACE, major cardiovascular adverse event; MI, myocardial infarction; OAD, oral antidiabetic drug; T2DM, type 2 diabetes mellitus. Marso SP et al. N Engl J Med 2016;375:
25 Ongoing and planned CVOTs in diabetes SUSTAIN 6 (Semaglutide, GLP-1RA) n=3297; duration ~2.8 years Q RESULTS CANVAS-R (Canagliflozin, SGLT2i) n=5826; duration ~3 years Completion Q VERTIS CV (NCT ) (Ertugliflozin, SGLT2i) n=8000; duration ~6.3 years Completion Q ALECARDIO (Aleglitazar, PPAR-αγ ) n=7226; follow-up 2.0 years Termin. Q RESULTS EMPA-REG OUTCOME (Empagliflozin, SGLT2i) n=7000; duration up to 5 years Q RESULTS CANVAS (Canagliflozin, SGLT2i) n=4418; duration 4+ years Completion Q DECLARE-TIMI-58 (Dapagliflozin, SGLT2i) n=17,276; duration ~6 years Completion Q EXAMINE (Alogliptin, DPP4i) n=5380; follow-up ~1.5 years Q RESULTS ELIXA (Lixisenatide, GLP-1RA) n=6000; duration ~4 years Q RESULTS FREEDOM (ITCA 650, GLP-1RA in DUROS) n=4000; duration ~2 years Q COMPLETED REWIND (Dulaglutide, QW GLP-1RA) n=9622; duration ~6.5 years Completion Q CREDENCE (cardio-renal) (Canagliflozin, SGLT2i) n=3700; duration ~5.5 years Completion Q SAVOR TIMI-53 (Saxagliptin, DPP-4i) n=16,492; follow-up ~2 years Q RESULTS LEADER (Liraglutide, GLP-1RA) n=9341; duration years Q RESULTS EXSCEL (Bydureon, QW GLP-1RA) n=14,000; duration ~7.5 years Completion Q HARMONY OUTCOME (Albiglutide, QW GLP-1RA) n~9400; duration ~4 years Completion Q TECOS (Sitagliptin, DPP-4i) n=14,000; duration ~4 5 years Q RESULTS DEVOTE (Insulin degludec, insulin) n=7637; duration ~5 years Q COMPLETED CARMELINA (Linagliptin, DPP-4i) n=8000; duration ~4 years Completion Q CAROLINA (Linagliptin, DPP-4i vs SU) n=6000; duration ~8 years Completion Q DPP-4i GLP-1RA SGLT2i Insulin PPAR-αγ CVOT, cardiovascular outcomes trial; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonist; QW, once weekly; SGLT2i, sodium glucose co transporter 2 inhibitor; SU, sulphonylurea ClinicalTrials.gov. Accessed February 17, 2017.
26 ADA/EASD consensus statement HbA1c 9% ( 75mmol/mol) Hypeglycemia HbA1c 10-12% ( mmol/mol) Inzucchi SE et al Diabetologia 2015; /s
27 Long-term effects of bariatric surgery (Swedish obese subjects study) Body weight Cumulative mortality Sjostrom et al, J Int Med, 2012
28 Conclusions Early diagnosis and good control from the start is critically important to prevent complications The different targets for high risk patients with long history of T2DM may be needed to avoid side effects of therapy At the moment, there are 3 antidiabetic medications with confirmed reduction of composite CV outcome vs placebo + standard of care: empagliflozin, liraglutide, and semaglutide Even with the positive effects of some antidiabetic treatments on CV outcomes, good control of other CV risk factors is still necessary Early combinational therapy might improve the long-term outcomes better than the stepwise intensification as suggested in the current algorithms
29 Thank you very much for your attention
Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists
Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists Robert R. Henry, MD Professor of Medicine University of California, San Diego Relevant Conflict
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationUpdate on Diabetes Cardiovascular Outcome Trials
Update on Diabetes Cardiovascular Outcome Trials Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationUpdate on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP
Update on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research InsAtute University of Miami Miller School of Medicine
More informationCardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials
Cardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials Rajiv Roy, MD Endocrinology Sharp Rees-Stealy Medical Group Background Between 1990 and 2010: Incidence of
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationDiabetes new challenges, new agents, new order
Diabetes new challenges, new agents, new order Ken Earle St Georges University Hospitals NHS Foundation Trust Overview Cardiovascular disease unmet needs Treating evident and residual risk Integrating
More informationCV outcomes Studies and Implications for diabetes management. Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH
CV outcomes Studies and Implications for diabetes management Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH Case 49 y female with the following medical problems DM typ2 Hypertension
More informationCase Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials
Case Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials Louis Kuritzky MD Clinical Assistant Professor Emeritus Department of Community Health and Family Medicine College of Medicine
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationCANVAS Program Independent commentary
CANVAS Program Independent commentary Cliff Bailey Aston University, Birmingham, UK 2017 Disclosures and disclaimers Clifford J Bailey CJB has attended advisory boards, undertaken ad hoc consultancy, received
More informationUpdates in Diabetes and Cardiovascular Disease Management: Are You Making the Link?
Updates in Diabetes and Cardiovascular Disease Management: Are You Making the Link? Denise Kolanczyk, PharmD, BCPS AQ Cardiology 1 Erika Hellenbart, PharmD, BCPS 2 Jennifer D Souza, PharmD, CDE, BC ADM
More informationManagement of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationMulti-factor approach to reduce cardiovascular risk in diabetes
Multi-factor approach to reduce cardiovascular risk in diabetes Prof. Nicola Napoli, MD PhD Division of Endocrinology and Diabetes Università Campus Bio-Medico di Roma Washington University in St Louis
More informationDiabetes and Heart Failure: The Role of SGLT2 Inhibitors
22 nd Annual Heart Failure 2018 Symposium Diabetes and Heart Failure: The Role of SGLT2 Inhibitors Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationLEADER Liraglutide and cardiovascular outcomes in type 2 diabetes
LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes Presented at DSBS seminar on mediation analysis August 18 th Søren Rasmussen, Novo Nordisk. LEADER CV outcome study To determine the effect
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationDiabetes and cardiovascular outcome trials. Cees J. Tack, internist
Diabetes and cardiovascular outcome trials Cees J. Tack, internist Take home messages (2013) Glucoseverlaging: beperkt effect op CV outcomes tijd nodig DPP-4 remmers: veilig, maar niet superieur Onverwachte
More informationOverview T2DM medications. Winnie Ho
Overview T2DM medications Winnie Ho Diabetes in Australia 1.7 million Australians with diabetes, of these 85% have T2DM 2-fold excess risk CV death in patients with diabetes Risk factor for progression
More information01/09/2017. Outline. SGLT 2 inhibitor? Diabetes Patients: Complex and Heterogeneous. Association between diabetes and cardiovascular events
MICROVASCULAR COMPLICATIONS Incidence of outcome g 1 Cardioprotective Effects of SGLT2s Relevant for Which T2 Diabetes Patient? SGLT 2 inhibitor? 58 year old, waist circumference 5 cm, PMH: IHD On statin,
More informationThe EMPA-REG OUTCOME trial: Design and results. David Fitchett, MD University of Toronto, Canada
The EMPA-REG OUTCOME trial: Design and results David Fitchett, MD University of Toronto, Canada Asian Cardio Diabetes Forum April 23 24, 2016 Kuala Lumpur, Malaysia Life Expectancy Is Reduced by ~12 Years
More informationCardiovascular risk in diabetes: What the Cardiologist Needs to Know. Hani Sabbour MD FACC FHRS
Cardiovascular risk in diabetes: What the Cardiologist Needs to Know Hani Sabbour MD FACC FHRS Years of life lost Hazard ratio (95% CI) (diabetes vs. no diabetes) CVD is the leading cause of death among
More informationCardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes
Biomarkers 2018 Cardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationUpdate on Cardiovascular Outcome Trials in Diabetes. Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013
Update on Cardiovascular Outcome Trials in Diabetes Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013 Residual Vascular Risk in People with Diabetes 2 Analyses based on 530,083 participants
More informationPreventing Serious Health Consequences of Type 2 Diabetes
Preventing Serious Health Consequences of Type 2 Diabetes The Evidence Hertzel C. Gerstein MD MSc FRCPC Professor and Population Health Institute Chair in Diabetes Research McMaster University and Hamilton
More informationIn compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure to the participants:
In compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure to the participants: Entity Activity Financial Consideration Comments Novo Nordisk
More informationCan Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure?
UCSD Hawaii 2017 Symposium Can Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure? Gregg C. Fonarow, MD, FACC, FAHA Elliot Corday Professor of Cardiovascular Medicine UCLA Division of Cardiology
More informationReview of FDA Guidance on Cardiovascular Outcomes for Diabetes Medication Trials and Application to Clinical Management
Katherine S. O Neal Pharm.D., MBA, BCACP, CDE, BC-ADM, AE-C Associate Professor The University of Oklahoma Health Sciences Center College of Pharmacy Department of Internal Medicine Oklahoma City, OK Member,
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationNewer Therapies for Type 2 Diabetes
Newer Therapies for Type 2 Diabetes Sandra Indacochea Sobel, MD Clinical Assistant Professor of Medicine Clinical Chief of Endocrinology, UPMC Mercy Division of Endocrinology, Diabetes, and Metabolism
More informationThe Death of Sulfonylureas? A Review of New Diabetes Medications
The Death of Sulfonylureas? A Review of New Diabetes Medications Kelly Hoenig, Pharm.D., BCPS Cedar Rapids Family Medicine Residency 2/4/17 Objectives Review GLP-1 Agonists, DPP-IV Inhibitors and SGLT-2
More informationDiabetes Management in CAD Patients. Stuart R. Chipkin, MD Research Professor School of Public Health and Health Sciences University of Massachusetts
Diabetes Management in CAD Patients Stuart R. Chipkin, MD Research Professor School of Public Health and Health Sciences University of Massachusetts Disclosure Stuart R. Chipkin, MD, FACE Nothing to disclose
More informationHalting the Rise, Newest Non- Insulin Options for Lowering A1c
Halting the Rise, Newest Non- Insulin Options for Lowering A1c Alecia Rottinghaus, PharmD PGY-1 Pharmacy Resident Iowa City Veterans Affairs Health Care System January 29 th, 2019 Disclosures Alecia Rottinghaus
More informationHalting the Rise, Newest Non- Insulin Options for Lowering A1c
Halting the Rise, Newest Non- Insulin Options for Lowering A1c Alecia Rottinghaus, PharmD PGY-1 Pharmacy Resident Iowa City Veterans Affairs Health Care System January 29 th, 2019 Disclosures Alecia Rottinghaus
More informationNew Strategies for Cardiovascular Risk reduction in Diabetes
New Strategies for Cardiovascular Risk reduction in Diabetes Dr. Godwin LEUNG Tat Chi MB ChB(HK), MRCP (UK), FHKCP, FHKAM (Medicine) FRCP (Glasg), FACC Specialist in Cardiology % event as first CV event
More informationUpdate Diabetes Therapie. Marc Y Donath
Update Diabetes Therapie Marc Y Donath Recent CV outcome studies in Diabetes N Engl J Med. 2015 373:2117-28 (Empa-Reg outcome study) N Engl J Med. 2016 June 13 (LEADER trial) N Engl J Med. 2017 June 12
More informationHelp the Heart. An Update on GLP-1 Agonists and SGLT2 Inhibitors. Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire
Help the Heart An Update on GLP-1 Agonists and SGLT2 Inhibitors Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire Mayo Clinic Grand Rounds May 16, 2017 2017 MFMER slide-1
More informationClinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs
Clinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs Professor Guntram Schernthaner Medical University of Vienna, Austria guntram.schernthaner@meduniwien.ac.at Agenda Glucose
More informationDiabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology
Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the
More informationPROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI. Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona
PROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona Disclosure Dr Massimo Boemi has been granted as speaker
More informationCardiovascular Consequences of Diabetes Mellitus
Cardiovascular Consequences of Diabetes Mellitus William J. Elliott, M.D., Ph.D. 05 MAY 18 Disclosure Statement The speaker s research and educational activities have been supported in the past (but NOT
More informationT2 Diabetes in Sep-16. Stephen Leow Disclosures. Why do we treat diabetes? Agenda. Targets
Stephen Leow Disclosures I have received honoraria, sat on the advisory boards or received grants from Novo Nordisk, Sanofi Aventis, Eli Lilly, Boehringer Ingleheim, Jansenn Cilag, Mundipharma, BioCSL,
More informationNewer Diabetes Treatments Drug Class Update with New Drug Evaluation: Semaglutide and Ertugliflozin
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More information2019 Update on Recent Guideline Releases for Diabetes, Hypertension, and Dyslipidemia: Can We, Please, All Just Get on the Same Page?!
2019 Update on Recent Guideline Releases for Diabetes, Hypertension, and Dyslipidemia: Can We, Please, All Just Get on the Same Page?! Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM Assistant Professor,
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Gretchen Ray, PharmD, PhC, BCACP, CDE Associate Professor, UNM College of Pharmacy January 28, 2018 gray@salud.unm.edu OBJECTIVES Describe the most
More informationCARDIOVASCULAR RISK FACTOR CONTROL IN TYPE 2 DIABETES MELLITUS AND NEW TRIAL EVIDENCE
CARDIOVASCULAR RISK FACTOR CONTROL IN TYPE 2 DIABETES MELLITUS AND NEW TRIAL EVIDENCE *Peter M. Nilsson Department of Clinical Sciences, Lund University, Skåne University Hospital, Malmö, Sweden *Correspondence
More informationEducational Objectives
Educational Objectives Recognize the rationale for cardiovascular outcome trials (CVOTs) in T2DM and review data from recent CVOTs of anti hyperglycemic agents Examine alignment of managed care T2DM treatment
More informationType 2 Diabetes Management: Case 1: Reducing Hypoglycemic Risk Case 2: Reducing Cardiovascular Risk
Type 2 Diabetes Management M. Susan Burke, MD, FACP Clinical Associate Professor of Medicine Sidney Kimmel Medical College at Thomas Jefferson University Senior Advisor, Lankenau Medical Associates Lankenau
More informationCardiovascular Impact of Medications for Treating Type 2 Diabetes
Friday CME Breakfast Lecture Cardiovascular Impact of Medications for Treating Type 2 Diabetes Thomas Blevins, MD Endocrinologist, Private Practice Texas Diabetes and Endocrinology Austin, Texas Educational
More informationTYP 2 DIABETES. Marc Donath
TYP 2 DIABETES Marc Donath Treatment of Typ 2 Diabetes GLP-1 Anti-IL-1β Insulin sulfonylureas Metformin UCP-1 IL-1β Sport SGLT2i Bariatric surgery Cardiomyocytes Control Glucose Dyntar et al. Diabetes
More informationDrug Class Update with New Drug Evaluation: Non-insulin Diabetes Treatments (SGLT-2 Inhibitors and GLP-1 Receptor Agonists)
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationTerapia con agonisti GLP1 e outcome cardiovascolare. Edoardo Mannucci
Terapia con agonisti GLP e outcome cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca,
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Jessica Conklin, PharmD, PhC, BCACP, CDE, AAHIP Associate Professor, UNM College of Phar macy jeconklin@salud.unm.edu Luis Gonzales, PharmD, PhC UNM
More informationFaculty. Robert S. Busch, MD, FACE Director of Clinical Research Albany Medical Faculty: Community Endocrine Group Albany, NY
Faculty Robert S. Busch, MD, FACE Director of Clinical Research Albany Medical Faculty: Community Endocrine Group Albany, NY 2 Disclosures Robert S. Busch, MD, FACE serves as a speaker for Astra Zeneca,
More informationLa lezione dei trials di safety cardiovascolare. Edoardo Mannucci
La lezione dei trials di safety cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer
More informationNEW DIABETES CARE MEDICATIONS
NEW DIABETES CARE MEDICATIONS James Bonucchi DO, ECNU, FACE Adult Medicine and Endocrinology Specialists Disclosures Speakers bureau Sanofi AZ BI Diabetes Diabetes cost ADA 2017 data Ever increasing disorder.
More informationType 2 diabetes & Cardiovascular disease. update. Barcelona, March 15th 2018
Type 2 diabetes & Cardiovascular disease update Barcelona, March 15th 2018 Francesc Xavier Cos Claramunt Sant Martí de Provençals. Head of Innovation and Health in Barcelona city Assoc.ProfUniversitatAutonomade
More informationCOPYRIGHT. Treatment of Type 2 Diabetes: What To Do When Treatment with Metformin is Inadequate? Can We Achieve Therapeutic Goals More Safely?
Treatment of Type 2 Diabetes: What To Do When Treatment with Metformin is Inadequate? Can We Achieve Therapeutic Goals More Safely? Martin J. Abrahamson, MD FACP Associate Professor of Medicine, Harvard
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationCardiologists and HbA1c: Novel Diabetes Drugs and the Cardiologist as Diabetician
Biomarkers 2019 Cardiologists and HbA1c: Novel Diabetes Drugs and the Cardiologist as Diabetician Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationGlucose Lowering Medications and CV Risk Reduction: A New Era Jane EB Reusch MD ADA President for Medicine and Science
Glucose Lowering Medications and CV Risk Reduction: A New Era Jane EB Reusch MD ADA President for Medicine and Science Professor of Medicine, Division of Endocrinology, Metabolism and Diabetes and Associate
More informationCanadian Journal of Diabetes
Can J Diabetes 42 (2018) S88 S103 Contents lists available at ScienceDirect Canadian Journal of Diabetes journal homepage: www.canadianjournalofdiabetes.com 2018 Clinical Practice Guidelines Pharmacologic
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationDISCLOSURES. Learning objectives NAVIGATING THE TREATMENT OF TYPE 2 DIABETES: WHAT S NEW? Investigator Initiated Trial Support:
NAVIGATING THE TREATMENT OF TYPE 2 DIABETES: WHAT S NEW? Jane E-B Reusch MD Professor of Medicine, Biochemistry and Bioengineering Associate Director Center for Women s Health Research University of Colorado
More informationHow to apply novel outcome data. to clinical practice. Preventing Cardiovascular Disease in Patients with T2DM
Preventing Cardiovascular Disease in Patients with T2DM How to apply novel outcome data with GLP-1 RA to clinical practice Lars Rydén Department of Medicine K2 Karolinska Institutet Stockholm, Sweden Ljubljana
More informationOral Agents. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
Oral Agents Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What would your ideal diabetes drug do? Effective in lowering HbA1c No hypoglycaemia No effect on weight/ weight
More informationGLP-1 RECEPTOR AGONIST SHOULD I TRY IT? VERONICA BRADY, PHD, BC-ADM, CDE PROJECT ECHO JUNE 21, 2018
GLP-1 RECEPTOR AGONIST SHOULD I TRY IT? VERONICA BRADY, PHD, BC-ADM, CDE PROJECT ECHO JUNE 21, 2018 SOMETHING TO CONSIDER IF YOU COULD PRESCRIBE A MEDICATION FOR YOUR PATIENT WITH DIABETES THAT: DECREASED
More informationNo Increased Cardiovascular Risk for Lixisenatide in ELIXA
ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES JUNE 2015 Coverage of data from ADA 2015, June 5 9 in Boston, Massachusetts No Increased Cardiovascular Risk for Lixisenatide in ELIXA First Cardiovascular
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationTHE EVOLUTION OF CLINICAL TRIALS IN T2DM: FROM TARGETING A1C TO TARGETING CARDIOVASCULAR OUTCOMES
Learning Objectives 1) Evaluate the interrelationship between diabetes, glycemic control, and cardiovascular disease. 2) Examine the evolution of type 2 diabetes (T2DM) drug development and factors leading
More informationEndocrinologist Sweetgrass Endocrinology
Endocrinologist Sweetgrass Endocrinology Sanders, Cummings Ask Justice Department to Investigate Insulin Prices The Department of Justice and the FTC are asked to investigate whether Lilly, Novo Nordisk,
More informationActualités en diabétologie Quoi de neuf en 2016? S. Aouiche Service de diabétologie CHU Mustapha Alger.Pr BOUDIBA
Actualités en diabétologie Quoi de neuf en 2016? S. Aouiche Service de diabétologie CHU Mustapha Alger.Pr BOUDIBA Deux médicaments valent mieux qu un dans le traitement du patient diabétique Jochen.SEUFERT
More informationDisclosures. Objectives. Bryan Cardiology Conference DM2 & Cardiovascular Outcome Trials 8/28/2017
Bryan Cardiology Conference DM2 & Cardiovascular Outcome Trials Shannon Wakeley MD Complete Endocrinology 9/2/2017 Disclosures Speakers Bureau: Astra Zeneca, Sanofi, Abbvie, Boehringer-Ingelheim, Medtronic,
More informationrazionale della combinazione insulina/glp-1 RAs
Insulina e GLP-1 RAS: insieme o separati? razionale della combinazione insulina/glp-1 RAs Catania Mercure Catania Excelsior 10 ottobre 2017 Andrea Giaccari andrea.giaccari@unicatt.it Centro per le Malattie
More informationCardiovascular outcome trials in diabetes: what have we learnt?
Diabetes Cardiovascular outcome trials in diabetes: what have we learnt? Mike Kirby, GP and Visiting Professor, The University of Hertfordshire and The Prostate Centre, London; Nick Boon, Honorary Reader,
More informationOral Agents in Type 2 DM
Oral Agents in Type 2 DM CME Away India & Sri Lanka March 23 - April 7, 2018 Richard A. Bebb MD, ABIM, FRCPC Consultant Endocrinologist Medical Subspecialty Institute Cleveland Clinic Abu Dhabi Copyright
More informationPeter Stein, MD Janssen Research and Development
New Agents and Technologies in the Pipeline for the Treatment of Patients with Diabetes Peter Stein, MD Janssen Research and Development Agents in Phase 3 Development for T2DM Long-acting GLP-1 analogues
More informationStephen Clement M.D. CDE Medical Director, Endocrine Services Inova Fairfax Hospital
Stephen Clement M.D. CDE Medical Director, Endocrine Services Inova Fairfax Hospital Financial Disclosures Consulting Panel for GSK on Hepatitis Vaccines Case Study BH is a 67 y/o female with T2 DM for
More information6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE
Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE 1 2 3 Sulfonylureas Glipizide Glyburide Glimeperide 4 Metformin Gold
More informationCardiovascular Management of a Patient with Diabetes
Cardiovascular Management of a Patient with Diabetes Dr Jeremy Krebs Clinical Leader Endocrinology and Diabetes Wellington Hospital Summary People with diabetes take a lot of medication Compliance and
More informationNew Therapies for Type 2 Diabetes
New for Type 2 Diabetes Joshua J. Joseph, MD Assistant Professor of Medicine Division of Endocrinology, Diabetes and Metabolism The Ohio State University Wexner Medical Center Financial Disclosures: None
More informationNew Therapies for Type 2 Diabetes
New for Type 2 Diabetes Joshua J. Joseph, MD Assistant Professor of Medicine Division of Endocrinology, Diabetes and Metabolism The Ohio State University Wexner Medical Center Financial Disclosures: None
More informationIntensifying Treatment Beyond Monotherapy in T2DM: Where Do Newer Therapies Fit?
Intensifying Treatment Beyond Monotherapy in T2DM: Where Do Newer Therapies Fit? Vanita R. Aroda, MD Scientific Director & Physician Investigator MedStar Community Clinical Research Center MedStar Health
More informationDapagliflozin and cardiovascular outcomes in type 2
EARN 3 FREE CPD POINTS diabetes Leader in digital CPD for Southern African healthcare professionals Dapagliflozin and cardiovascular outcomes in type 2 diabetes Introduction People with type 2 diabetes
More informationManaging Perioperative Diabetes What s new? Kathryn A. Myers MD FRCPC Chair Chief Division of GIM Professor of Medicine Western University
Managing Perioperative Diabetes What s new? Kathryn A. Myers MD FRCPC Chair Chief Division of GIM Professor of Medicine Western University Objectives: By the end of this session, you will be able to: Identify
More informationSafety profile of Liraglutide: Recent Updates. Mohammadreza Rostamzadeh,M.D.
Safety profile of Liraglutide: Recent Updates Mohammadreza Rostamzadeh,M.D. Pancreatitis: Victoza post-marketing experience: spontaneous reports of pancreatitis For the majority of the cases, there is
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationSodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol
Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has
More informationType 2 diabetes and cardiovascular risk: the role of GLP-1
Type 2 diabetes and cardiovascular risk: the role of GLP-1 Dr Isidora Kitsou-Mylona, PhD Novo Nordisk Regional Medical Advisor Business Area Africa, Gulf & India Disclaimer I am an employee of Novo Nordisk
More informationDr Tahseen A. Chowdhury Royal London Hospital. New Guidelines in Diabetes: NICE or Nasty?
Dr Tahseen A. Chowdhury Royal London Hospital New Guidelines in Diabetes: NICE or Nasty? I have no conflicts of interest I do not undertake talks / advisory bodies / research for any pharma company Consultant
More informationThe Flozins Quest for Clarity?
The Flozins Quest for Clarity? Choosing Wisely with Academic Detailing 2018 ARE THEY THE REAL DEAL Disclosure statements The Academic Detailing Service is operated by Dalhousie Continuing Professional
More informationDiabetes and New Meds for Cardiovascular Risk Reduction. F. Dwight Chrisman, MD, FACC. Disclosures: BI Boehringer Ingelheim speaker
Diabetes and New Meds for Cardiovascular Risk Reduction F. Dwight Chrisman, MD, FACC Disclosures: BI Boehringer Ingelheim speaker 1 Prevalence of DM DM state specific prevalence 2006 4%-6% 6-8% 8-10% 10-12%
More informationGLP-1 receptor agonists for type 2 diabetes currently available in the U.S.
GLP-1 receptor agonists for type 2 diabetes currently available in the U.S. GLP-1 agonists are a class of antidiabetic agents that mimic the actions of the glucagon-like peptide. GLP-1 is one of several
More informationDiabetes Mellitus case studies. Jana Vinklerová
Diabetes Mellitus case studies Jana Vinklerová Definition of diabetes (metabolic disorder) Chronically raised blood glucose (hyperglycaemia) Insulin/Glucagon Insulin is responsible for lowering glucose
More informationEmpagliflozin (Jardiance ) for the treatment of type 2 diabetes mellitus, the EMPA REG OUTCOME study
Empagliflozin (Jardiance ) for the treatment of type 2 diabetes mellitus, the EMPA REG OUTCOME study POSITION STATEMENT: Clinicians should continue to follow MHRA advice and NICE technology appraisal guidance
More informationMichael Mansfield Consultant Leeds Teaching Hospitals
Easing, fixing and avoiding diabetic hyperglycaemia: new drugs, new approaches Michael Mansfield Consultant Leeds Teaching Hospitals Declaration: no significant gifts, fees, funding from pharma Topics:
More informationEmpagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
Diabetes Ther (2017) 8:33 53 DOI 10.1007/s13300-016-0211-x REVIEW Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus John E. Anderson. Eugene E. Wright Jr.. Charles F.
More information